TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Key Points

• TB Alternative Assets Ltd. reduced its holdings in BioNTech SE by 25.8%, owning 28,917 shares after selling 10,079 shares in the second quarter.
• BioNTech has received multiple analyst upgrades, with a consensus rating of "Moderate Buy" and an average price target of $134.56.
• The company reported a $306.46 million revenue for the last quarter, significantly exceeding estimates, despite missing earnings per share targets.

TB Alternative Assets Ltd. cut its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 25.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,917 shares of the company's stock after selling 10,079 shares during the quarter. BioNTech makes up approximately 0.6% of TB Alternative Assets Ltd.'s holdings, making the stock its 24th largest holding. TB Alternative Assets Ltd.'s holdings in BioNTech were worth $3,079,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech during the first quarter worth approximately $36,000. Banque Transatlantique SA acquired a new position in BioNTech during the 1st quarter worth $80,000. Costello Asset Management INC bought a new stake in shares of BioNTech in the 1st quarter worth about $91,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech in the 1st quarter valued at about $105,000. Finally, NewEdge Advisors LLC bought a new position in shares of BioNTech during the first quarter worth about $167,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BNTX has been the topic of several research reports. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Morgan Stanley raised their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Leerink Partners set a $112.00 price objective on shares of BioNTech in a report on Monday, June 2nd. HC Wainwright reissued a "buy" rating and set a $136.00 target price on shares of BioNTech in a report on Monday, September 8th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $155.00 price target (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $134.56.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $99.75 on Thursday. The stock has a market cap of $23.98 billion, a price-to-earnings ratio of -62.34 and a beta of 1.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $129.27. The stock's 50 day moving average price is $106.60 and its 200 day moving average price is $103.25.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter last year, the business posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.